"Even in a high-inflation, post-pandemic market, the group as a whole saw overall benefit costs similar to the prior year.... Modest stop loss premium increases did not rise to meet historically high claims, resulting in heightened loss ratios for insurers and sweet (but likely temporary) relief for employers.... Despite a 24% increase in rebates, gross Rx spend (i.e., before rebates) for the group soared 30% from one year to the next."  MORE >>